Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 4/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21780866 | 0.89 | KMO (0.46) | KMOEGFRGLSHTR2AHTR2C | |
| SCHEMBL30928551 | 0.86 | KMO (0.44) | KMOEGFRGLSHTR2AHTR2C | |
| SCHEMBL13528 | 0.86 | KMO (0.44) | KMOEGFRGLSHTR2AHTR2C | |
| SCHEMBL109465 | 0.85 | KMO (0.50) | KMOEGFRGLSHTR2AHTR2C | |
| SCHEMBL29804486 | 0.83 | KMO (0.52) | KMOEGFRGLSHTR2AHTR2C | |
| SCHEMBL21183580 | 0.83 | KMO (0.49) | KMOEGFRGLSHTR2AHTR2C | |
| SCHEMBL15447295 | 0.83 | KMO (0.52) | KMOEGFRGLSHTR2AHTR2C | |
| SCHEMBL27799511 | 0.83 | KMO (0.50) | KMOEGFRGLSHTR2AHTR2C | |
| SCHEMBL23533615 | 0.83 | EGFR (0.55) | KMOEGFRGLSHTR2AHTR2C | |
| SCHEMBL14910174 | 0.83 | MAOB (0.51) | KMOEGFRGLSHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2485591-B1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| US-8563543-B2 | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563543-B2 | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120189642-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | SCHERING CORPORATION (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120189642-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | SCHERING CORPORATION (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2011044187-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | SCHERING CORPORATION (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120189642-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, APP, BACE2 | KMO 2129/4885EGFR 1940/4885GLS 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.